Form 4 for JAZZ Jazz Pharmaceuticals plc
Accepted 2022-07-07 00:00:00 ET · period of report 2022-07-05 · accession 0001765581-22-000069 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| D | 2022-07-07 | 2022-07-05 | JAZZ | Tovey Christopher J. | EVP, COO, Managing Dir E | M - OptEx | $0.02 | +4,032 | 19.9K | +25% | +$80.64 |
| DM | 2022-07-07 | 2022-07-05 | JAZZ | Tovey Christopher J. | EVP, COO, Managing Dir E | S - Sale+OE | $160.00 | -5,209 | 14.7K | -26% | -$833.4K |
| D | 2022-07-07 | 2022-07-05 | JAZZ | Tovey Christopher J. | EVP, COO, Managing Dir E | M - OptEx | $0.00 | -4,032 | 4,031 | -50% | $0 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Ordinary Shares | 2022-07-05 | M | A | 4,032 | $0.02 | 19,872 | D | — | — | |
| 2 | Common | Ordinary Shares | 2022-07-05 | S | D | 4,032 | $160.00 | 15,840 | D | — | — | |
| 3 | Common | Ordinary Shares | 2022-07-05 | S | D | 1,177 | $160.00 | 14,663 | D | — | — | |
| 4 | Derivative | Non-Qualified Stock Option (right to buy) | 2022-07-05 | M | D | 4,032 | $0.00 | 4,031 | D | $0.02 · — to 2031-02-22 | 4,032 Ordinary Shares | (F2) Option to acquire Jazz Ordinary Shares received upon conversion of options to acquire shares of GW Pharmaceuticals PLC ("GW") pursuant to the GW Transaction Agreement among Jazz Pharmaceuticals UK Holdings Limited, Jazz Pharmaceuticals Public Limited Company and GW dated February 3, 2021 (the "Merger"). The effective date of the Merger was May 5, 2021. Fifty percent of the award will vest and be available for exercise on February 22, 2022 and fifty percent will vest and be available for exercise on February 22, 2023 in accordance with the terms of the Merger. |